The Muscular Dystrophy Association has awarded $120,000 to Cambridge, Mass.-based Catabasis Pharmaceuticals. The award is part of a strategic partnership under which the pharmaceutical company will test two compounds — CAT-1004 and CAT-1040 — in the mdx research mouse model of Duchenne muscular dystrophy (DMD).
The award was made through MDA Venture Philanthropy (MVP), the drug development arm of MDA's translational research program.
Catabasis plans to demonstrate in the new four-month study that CAT-1004 reduces inflammation in muscle tissue and improves muscle function. It will compare CAT-1004, CAT-1040 and prednisolone to identify the most effective compound. If favorable results are obtained, the company plans to begin clinical trials in people with DMD.
Catabasis has completed a safety, tolerability and pharmacokinetics (what the body does to a drug) study of CAT-1004 in healthy human volunteers over an eight-week trial period. It has an open Investigational New Drug application for the compound with the U.S. Food and Drug Administration, which allows it to conduct clinical trials of the investigational drug in the United States.
To learn more, read MDA Funds Testing of Anti-Inflammatory Compounds for DMD.